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Protocol
AbstrACt
Introduction Single-incision mini-slings (SIMS) represent 
the third generation of midurethral slings. They have been 
developed with the aim of offering a true ambulatory 
procedure for treatment of female stress urinary 
incontinence (SUI) with reduced morbidity and earlier 
recovery while maintaining similar efficacy to standard 
midurethral slings (SMUS). The aim of this study is to 
determine the clinical and cost-effectiveness of adjustable 
anchored SIMS compared with tension-free SMUS in the 
surgical management of female SUI, with 3-year follow-up.
Methods and analysis A pragmatic, multicentre, non-
inferiority randomised controlled trial.
Primary outcome measure The primary outcome 
measure is the patient-reported success rate measured 
by the Patient Global Impression of Improvement at 
12 months. The primary economic outcome will be 
incremental cost per quality-adjusted life year gained at 
12 months. 
secondary outcome measures The secondary outcomes 
measures include adverse events, objective success rates, 
impact on other lower urinary tract symptoms, health-
related quality of life profile and sexual function, and 
reoperation rates for SUI. Secondary economic outcomes 
include National Health Service and patient primary and 
secondary care resource use and costs, incremental cost-
effectiveness and incremental net benefit. 
statistical analysis The statistical analysis of the primary 
outcome will be by intention-to-treat and also a per-
protocol analysis. Results will be displayed as estimates 
and 95% CIs. CIs around observed differences will then 
be compared with the prespecified non-inferiority margin. 
Secondary outcomes will be analysed similarly.
Ethics and dissemination The North of Scotland 
Research Ethics Committee has approved this study 
(13/NS/0143). The dissemination plans include HTA 
monograph, presentation at international scientific 
meetings and publications in high-impact, open-access 
journals. The results will be included in the updates of the 
National Institute for Health and Care Excellence and the 
European Association of Urology guidelines; these two 
specific guidelines directly influence practice in the UK 
and worldwide specialists, respectively. In addition, plain 
English-language summary of the main findings/results 
will be presented for relevant patient organisations.
trial registration number ISRCTN93264234. The SIMS 
study is currently recruiting in 20 UK research centres. 
The first patient was randomised on 4 February 2014, with 
follow-up to be completed at the end of February 2020.
background
Urinary incontinence (UI) is a common and 
potentially debilitating condition among 
women.1 In the UK, the estimation for clini-
cally significant UI symptoms (age >40 years) 
was 6 million women (40%), with 1 million 
women (6.2%) reporting to be significantly 
bothered by their symptoms. UI was socially 
disabling in 0.33 million (2.2%).2 UI has a 
negative impact on a woman’s social, phys-
ical and psychological well-being, leading to 
embarrassment, low self-esteem and social 
isolation. UI is associated with negative effects 
on the productivity of working women, with 
some avoiding employment because of fear 
of embarrassing situations.3 UI has significant 
cost implications to the individual and the 
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health service. The total annual cost to the UK National 
Health Service (NHS) for the management of women 
over the age of 40 with UI was £301 million or 0.3% of the 
NHS budget.4 Costs borne by women in terms of out-of-
pocket expenses were £230 million5 or £290 per woman 
per year.6 All values reported are inflated to 2009 values.
Stress urinary incontinence (SUI) is the most common 
type of UI in premenopausal women, accounting 
for almost 50% of cases.7 It is defined as involuntary 
leakage of urine on effort, or exertion, or on sneezing 
or coughing. Initial management of SUI includes 
conservative therapy such as pelvic floor muscle training 
(PFMT), biofeedback, electrical stimulation or drugs. 
When conservative therapy fails, in about one-third of 
cases, surgery is the next option7 Of the surgical treat-
ments available, tension-free standard midurethral slings 
(SMUS; retropubic tension-free vaginal tape (RP-TVT) 
and transobturator tension-free vaginal tape (TO-TVT)) 
are the most commonly performed procedures for 
SUI, resulting in 11 000 finished consultant episodes in 
England in 2009–2010, with estimated costs of £2044/
procedure,8 that is, a total of £22.5 million/year. The 
Cochrane review of minimally invasive midurethral slings 
(MUS)9 concluded that there was no evidence of signif-
icant differences in patient-reported outcomes between 
RP-TVT and TO-TVT, and therefore the control arm for 
the proposed randomised controlled trial (RCT) is a 
pragmatic combination of these two types of SMUS. Anal-
ysis of British Society of Urogynaecology database showed 
that the vast majority of SMUS in the UK are done under 
general anaesthesia (GA) or deep intravenous patient 
sedation.10
Single-incision mini-slings (SIMS) represent the third 
generation of MUS; they have been developed with the 
aim to offer a true ambulatory procedure for treatment 
of SUI with reduced morbidity and earlier recovery while 
maintaining similar efficacy to SMUS. The National Insti-
tute for Health and Care Excellence (NICE) undertook 
an interventional procedure overview of SIMS1 for the 
management of SUI in women in July 2007 (NICE guid-
ance/IP398): there was no RCT evidence and only small 
case series data were available. The report concluded 
that the current evidence on the safety and efficacy of 
SIMS was inadequate in quality and quantity, and recom-
mended that SIMS should only be performed in the 
context of research. Similarly, the Cochrane review of 
minimally invasive MUS found no randomised evidence 
evaluating SIMS.9
rationale for the study
The European guidelines11 on the management of 
urinary incontinence describe two concepts of MUS for 
the surgical treatment of SUI in women: (1) Tension-free 
MUS that include all MUS that depend on their post-in-
sertion fixation mechanism on friction to nearby tissues 
within their relatively long trajectory of insertion such as 
SMUS (both RP-TVT and TO-TVT); one type of non-an-
chored SIMS (Contasure-Needleless) also fits into this 
group. (2) Anchored MUS that include all other SIMS 
and other anchored slings such as Remeex TRT; the latter 
is mainly used in women with recurrent SUI.12 13 SIMS 
fundamentally differs from SMUS because they have 
a shorter trajectory of insertion and therefore need a 
robust anchoring mechanism to the obturator complex 
with a strong post-insertion pull-out force. All currently 
available SIMS share the same tape material (type 1 poly-
propylene) and the insertion technique through a single 
vaginal incision; however, they differ in the type/robust-
ness of the anchorage mechanism used.14 15 A number of 
recently developed SIMS, such as Ajust, Altis, and TFS, 
have an added advantage that allow post-anchorage 
adjustment of the sling tension and have been shown in 
independent animal studies, assessing their immediate 
and delayed extraction forces, to be associated with the 
strongest and most robust anchoring mechanism to the 
obturator complex.14 15
A multicentre prospective cohort study of adjustable 
anchored SIMS-Ajust in 100 women has shown its accept-
ability (75%) and feasibility (97%) to be done under local 
anaesthesia (LA).16 We recently concluded our multi-
centre prospective pilot RCT17 where 137 women were 
randomised to adjustable anchored SIMS-Ajust (n=69), 
performed under LA, versus SMUS (TVT-O; n=68). At a 
minimum of 12 months’ follow-up, there were no signif-
icant differences in the patient-reported success rate 
(OR 0.895; 95% CI 0.344 to 2.330; p=1.000), objectives 
success rate (OR 0.929; 95% CI 0.382 to 2.258; p=1.00) 
and reoperation rates (OR 0.591; 95% CI 0.136 to 2.576; 
p=0.721) between both groups. Comparable number of 
women reported significant improvement in their quality 
of life (QoL) (p=0.190) and sexual function (p=0.699) 
in both groups. Similar results were recently reached by 
a Deutsch group in a similar small RCT. Similar results 
were reported in observational studies with varying 
cohort sizes: patient-reported and objective success rates 
of 85%–91% up to 12-month follow-up.18–21
A recent updated systematic review and meta-analysis22 
compared the effectiveness and complications of SIMS 
versus SMUS for the surgical management of female SUI. 
The authors considered TVT-Secur to be clinically irrel-
evant, having been excluded from clinical practice and 
excluded the relevant RCTs, hence included a total of 
26 RCTs (n=3308 women). Meta-analyses showed that at 
a mean follow-up of 18 months, there was no evidence 
of significant differences between SIMS and SMUS in 
patient-reported and objective cure rates (relative risk 
(RR): 0.94; 95% CI 0.88 to 1.00; and RR: 0.98; 95% CI 0.94 
to 1.01, respectively). Interestingly, SIMS had significantly 
lower postoperative pain scores, earlier return to normal 
activities and earlier return to work (weighted mean differ-
ence (WMD): −2.94; 95% CI −4.16 to −1.73; WMD: −5.08; 
95% CI −9.59 to −0.56; and WMD: −7.20; 95% CI −12.43 
to −1.98, respectively). The authors reported that SIMS 
had a trend towards higher rates of repeat continence 
surgery, although it did not reach statistical significance 
(RR: 2.00; 95% CI 0.93 to 4.31). An exploratory subgroup 
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analysis evaluating adjustable anchored SIMS (Ajust and 
TFS) versus TO-TVT included four RCTs and showed no 
evidence of significant differences in patient-reported 
or objective cure rates. However, it is important to note 
that they found no RCTs evaluating Altis.22 The authors 
concluded that ‘on excluding TVT-Secur, there was no evidence 
of significant differences in patient-reported and objective cure 
between currently used SIMS and SMUS at midterm follow-up 
while associated with more favourable recovery time’.22 The 
authors urged caution in the interpretation of results due 
to the heterogeneity of the small trials included, lack of 
blinding of the assessors which can be a source of bias, the 
level of incomplete data leading to attrition bias and the 
relatively short term of follow-up.
Evidence of longer term outcomes for adjustable 
anchored SIMS are now emerging. In July 2012, Sivaslioglu 
et al23 reported a 5-year follow-up for their RCT of TFS 
versus SMUS (n=80). The results showed no evidence of 
significant difference in objective and patient-reported 
success rates (TFS 83%–89% vs SMUS 75%–78%, respec-
tively). Similarly, Naumann et al24 reported a 2-year 
follow-up of observational study of 51 women who under-
went SIMS-Ajust; the patient-reported success rate was 
86%.
The cost-effectiveness of any new technology is a 
prerequisite for its adoption in clinical practice. Our 
team performed the first health economic analysis of 
adjustable anchored SIMS (Ajust) compared with SMUS 
(TVT-O).25 The health economic outcome measures 
were incremental costs to the health services, patient 
quality-adjusted life year (QALYs) and incremental cost 
per QALY. Results have shown an incremental total cost 
savings to the health service of £142/procedure with 
adjustable anchored SIMS, not counting the further 
potential economic gain of earlier return to work in 
these women. There were no significant differences 
in QALYs generated compared with SMUS: 95% CI 
−0.008 to 0.002. Assuming these results were general-
isable to all currently performed MUS procedures in 
England and Wales (approximately 11 000 in 2010),10 
our analyses suggest the potential for substantial cost 
savings to the NHS in the UK of about £1.5 million per 
year. However, these results have to be confirmed in the 
definitive RCT.
The above evidence has led to a consensus among urol-
ogists and urogynaecologists that an adequately powered 
RCT with clinical effectiveness as the primary end point 
is now timely and required to inform surgeons, patients 
and decision makers with the most clinically effective, 
cost-effective surgical treatment for primary SUI, which 
is associated with the least burden on patients’ QoL and 
NHS resources.
study objectives
The aim of this pragmatic multicentre RCT is to deter-
mine the clinical effectiveness and cost-effectiveness of 
adjustable anchored SIMS compared with tension-free 
SMUS in the surgical management of female SUI.
The hypothesis being tested is that patient-reported 
success rate following surgical treatment with adjustable 
anchored SIMS procedures is non-inferior to tension-free 
SMUS, while the former is associated with less postop-
erative pain, shorter hospital stay, earlier recovery and 
consequently earlier return to usual activities/work, and 
is more cost-effective than SMUS.
The primary objective is to compare SUI outcomes in 
terms of patient-reported success rates as measured by the 
Patient Global Impression of Improvement (PGI-I) at 12 
months.
The primary economic objective is to compare cost-ef-
fectiveness measured in terms of QALYs derived from 
responses to the EQ-5D and the ICIQ-LUTSqol over the 
follow-up period.
The secondary objectives are to compare objective 
success rates (24-hour pad test/home cough stress test) 
and other patient-reported outcomes, including post-
operative pain scores and health-related QoL using the 
ICIQ-LUTSqol, impact on other urinary symptoms (Inter-
national Consultation on Incontinence Questionnaire 
— Female Lower Urinary Tract Symptoms (ICIQ-FLUTS)), 
impact on sexual function (ICIQ-FLUT-Sex/PISQ-IR), 
complication rates, disease recurrence and costs to the 
NHS and patients.
MEthods
Study design
This is a pragmatic, multicentre, non-inferiority RCT 
comparing adjustable anchored SIMS with tension-free 
SMUS in surgical management of SUI in women. The 
trial structure is presented below (figure 1).
Intervention to be evaluated
The interventions being compared are (1) tension-free 
SMUS, including RP-TVT and TO-TVT, and (2) adjust-
able anchored SIMS, which fulfil the following criteria 
of robust anchorage and postinsertion adjustability:
 ► SIMS is made of type 1 polypropylene mesh: monofil-
ament and macroporous (pore size=75 μm)
 ► robustly anchored to obturator complex (robust in-
sertion is defined as immediate pullout force=12 New-
tons (N) and/or 4 weeks’ pullout force=30N)
 ► fully adjustable sling postinsertion
 ► proven feasibility to be done under LA
 ► minimum of level 2 evidence showing their safety and 
short-term (minimum 3 months) patient-reported 
outcomes.
SMUS will be performed under GA or deep intravenous 
sedation, while adjustable anchored SIMS will be done 
under LA as an opt-out policy (ie, LA will be the standard 
type of anaesthesia for adjustable anchored SIMS unless 
specifically declined by a participant requesting GA). 
Furthermore, participant’s requests for conversion to GA 
will be respected at any stage of the procedure. A standard 
LA protocol, which we have previously published and 
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successfully used in two previous studies,16 17 will be used 
as a guidance (online supplementary appendix 1).
All participants, in both arms, will receive preop-
erative analgesia (30–60 min prior to the operation): 
paracetamol and non-steroidal anti-inflammatory drug 
(diclofenac sodium or ibuprofen); a vaginal application 
of EMLA cream (a 5% emulsion preparation, containing 
2.5% each of lidocaine/prilocaine); and optional 10 mL 
of intraurethral Instillagel (anaesthetic, antiseptic lubri-
cant). All participants would receive preoperative/
intraoperative prophylactic broad spectrum antibiotics. 
A cystoscopy (rigid or flexible) will be performed in all 
women following insertion of the sling, regardless of the 
study arm. It is worth noting that rigid cystoscopy was well 
tolerated by all women under LA in the pilot RCT. No 
vaginal packs or catheters would be routinely inserted. 
Figure 1 SIMS study flow chart. ICIQ-FLUTS, International Consultation on Incontinence Questionnaire — Female Lower 
Urinary Tract Symptoms; NRS, Numerical Rating Scale; PFMT, pelvic floor muscle training; SIMS, single-incision mini-slings; 
SUI, stress urinary incontinence; UPS, Urgency Perception Scale.
group.bmj.com on August 25, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
 5Abdel-Fattah M, et al. BMJ Open 2017;7:e015111. doi:10.1136/bmjopen-2016-015111
Open Access
Postoperatively all participants will undergo voiding 
assessment, including assessment for postvoiding residual 
urine volume (PVR) using a bedside bladder scanner 
(online supplementary appendix 2, guidance protocol 
and flow chart for postoperative voiding assessment).
Adjustable anchored SIMS
A standard combination of fast and delayed action LA 
(dose-dependent on participant’s body weight) will be 
infiltrated vaginally into either side of the urethra, the 
vaginal angles (sulci) and behind the inferior pubic ramus 
into the obturator complex (eg, using a curved black 
spinal needle and/or pudendal block needle). Women 
will be accompanied by a nurse for support. All partici-
pating surgeons will use an adjustable anchored SIMS that 
meets the prespecified criteria described below. A stan-
dardised insertion technique will be used by all surgeons 
following the original description of the particular SIMS 
used. Most adjustable anchored SIMS, however, have a 
fairly similar procedure of insertion. We describe below 
the standard insertion steps for the adjustable anchored 
SIMS (Ajust-CR Bard and Altis-Coloplast): women will 
be positioned in lithotomy position with hips flexed 
at 90°–100°. LA infiltration is as above; a suburethral 
vertical vaginal incision (~1.5 cm) will be made; and bilat-
eral paraurethral tunnels will be created reaching to the 
posterior margin of the inferior pubic ramus but without 
piercing the obturator membrane. Further infiltration of 
LA into the obturator membrane will be done, and SIMS, 
with the ‘fixed anchor’ end mounted on the applicator, 
would be introduced through the predissected paraure-
thral tunnel until reaching behind the inferior pubic 
ramus. The applicator would then pivot slowly behind 
the ramus and through the obturator complex allowing 
the fixed anchor to maintain its position in the obturator 
membrane and muscles at points equivalent to 10 and 2 
o’clock in relation to the urethral orifice. The insertion 
steps would be repeated on to the other side allowing the 
‘adjustable anchor’ to be fixed in the contralateral obtu-
rator complex. The SIMS is now robustly anchored and 
the tension would then be adjusted as required to achieve 
continence while avoiding voiding difficulty. Performing 
the cough stress test can prove very helpful in this adjust-
ment process and is recommended. The adjustable 
anchor would then be locked in the case of the Ajust (not 
required with Altis), and a cystoscopy will be performed 
to exclude perforation and the vaginal incision closed.
Tension-free SMUS
The choice of SMUS whether retropubic or transobtu-
rator will depend on the surgeon’s experience. We expect 
a 50% representation of each type of SMUS in the control 
arm.
Retropubic tension-free vaginal tape
RP-TVT will be type 1 polypropylene mesh (monofilament 
and macroporous: pore size ≥75 μm). The tension-free 
vaginal tape (TVT) procedure was developed by Ulmsten 
et al.26 The procedure will be done under GA or intra-
venous sedation as per the standard practice of each 
surgeon. The bladder will be emptied with a Foley cath-
eter. Close to the superior rim of the pubic bone, two 1 cm 
long transverse incisions 3 cm either side of the midline 
will be made after injection of LA into the abdominal 
skin just above the symphysis pubis, down along the back 
of the pubic bone to the retropubic space and vaginally 
into the periurethral area. An incision ~1.5 cm long will 
be made in the midline of the suburethral vaginal wall, 
followed by dissection of the periurethral tunnels to allow 
introduction of the TVT needle. A stent will be inserted 
into the Foley catheter to deviate the urethravesical junc-
tion away from the path of the needle. The TVT needle 
perforates the urogenital diaphragm and will be brought 
up to the abdominal incision ‘shaving’ the back of the 
pubic bone. The procedure will then be repeated on the 
other side, and a cystoscopy will be performed to exclude 
perforation. The cough stress test may then be performed, 
according to the surgeon’s standard technique, and the 
sling adjusted in a tension-free fashion and the incisions 
are closed.
Transobturator tension-free vaginal tape
TO-TVT will be type 1 polypropylene mesh (mono-
filament and macroporous: pore size ≥75 μm). All 
procedures will be performed under GA as originally 
described by Delrome27 and de Leval28 for the outside-in 
and inside-out routes, respectively. Women are positioned 
in lithotomy position with hips flexed at 100°–110°, and 
LA may be infiltrated into the vaginal angles; the latter 
is not a standard practice, however is recommended in a 
similar regimen to the one used in the adjustable SIMS 
insertion (above). A ~1.5 cm suburethral longitudinal 
vaginal incision will be made and bilateral paraurethral 
tunnels created reaching to the posterior margin of the 
inferior pubic ramus. Bilateral groin incisions are made 
1–2 cm lateral to the labiofemoral fold and 2 cm above 
the level of urethra. The transobturator trocar is inserted 
from groin incisions at 90° to pierce the obturator muscles 
and membranes and then guided by the surgeon’s finger 
to the vaginal incision. TO-TVT is then mounted on 
the trocar and the trocar is withdrawn in reverse order. 
The previous two steps are repeated on the contralateral 
side achieving TO-TVT suburethral placement, and the 
TO-TVT is then adjusted tension-free. For the inside-out 
technique of insertion, TO-TVT would be introduced in 
the reverse route from the vaginal incision towards the 
groin using the winged guide to protect the lower urinary 
tract (LUT). A cystoscopy will be performed to exclude 
LUT injury. Vaginal and skin incisions will then be closed.
study population
The study included women aged 18 years or over with 
SUI who have been referred to the collaborating surgical 
gynaecology, urology and urogynaecology units from 
across the UK for treatment of SUI for whom surgery has 
been indicated.
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Setting
The study will be done in secondary and tertiary care 
acute hospital settings across the UK. NHS Grampian will 
be the clinical coordinating centre and house the chief 
investigator.
Each unit will have at least one participating surgeon 
who is competent in performing SIMS under LA prior 
to enrolling in the RCT. Ideally, the surgeon will have 
performed 20 adjustable anchored SIMS procedures 
(with 10 performed under LA), within prospective audit 
and results submitted to a national surgical database. 
The chief investigator, or a delegated expert in SIMS, 
will provide training in SIMS under LA for enrolling 
surgeons as necessary and will ensure adequate expertise 
of surgeons in both arms. Surgeons will be experienced in 
at least one type of SMUS (RP-TVT or TO-TVT) and will 
have performed an adequate workload in the preceding 
2 years.
Selection of participants
Clinicians assess patients likely to require surgery for SUI 
as per standard clinical practice in their unit and as per 
national guidelines. Each unit will keep a log with brief 
details of all potentially eligible patients assessed in order 
to document the reasons for non-inclusion in the study 
(eg, reason they were ineligible, or declined to partici-
pate). This information will inform the trial CONSORT 
diagram.
Planned inclusion and exclusion criteria
Inclusion criteria
Inclusion criteria include women ≥18 years with urody-
namic stress incontinence/or urodynamic mixed UI with 
predominant SUI bothering symptoms, in whom surgery 
to treat SUI has been decided by the patient and her 
treating clinician. Women will have failed or declined 
conservative treatment (including supervised PFMT) 
and would have completed their families. In line with the 
NICE guidelines, the small group of women with pure 
SUI and no symptoms of overactive bladder (OAB) or 
voiding dysfunction (VD) can be included in the study 
without urodynamic investigations.
Preoperative urodynamic investigations include 
free uroflowmetry, PVR urine volume assessment 
and subtracted filling cystometry. Other tests such as 
urethral pressure profile and leak point pressure pres-
sures are not mandatory, however are welcome as they 
will inform a number of the preplanned secondary 
outcomes.
Exclusion criteria
Women will be excluded if they have one or more of the 
following:
 ► anterior or apical prolapse ≥POP-Q stage 2 (POP-Q, 
Pelvic Organ Prolapse Quantification score)
 ► previous surgery for SUI
 ► mixed incontinence with predominant OAB symp-
toms (defined as OAB failed to be controlled on con-
servative treatment, such as bladder retraining, PFMT 
and/or antimuscarinic treatment)
 ► neurological conditions, for example, multiple sclero-
sis (MS), spinal cord injuries
 ► concomitant surgery at time of SUI surgery
 ► previous pelvic irradiation
 ► pregnancy or planning for a family
 ► inability to understand the information leaflet and 
consent form in English.
Recruitment and study procedures
Identifying participants
Local procedures at the participating hospitals are 
different; hence, the timing and patients’ approach and 
the consent process will vary accordingly with special 
emphasis to meet individual patient’s needs. The patient 
information sheet will be sent to patients together with 
their clinic appointments where possible, ensuring that 
they have ample time (>24 hours) for consideration 
before being approached by the research team at the 
clinic.
Patients likely to require surgery for SUI and who 
meet the eligibility criteria will be identified at the 
preassessment clinics, urodynamic clinics and outpa-
tient urology/gynaecology clinics by the consultant, 
research nurse (RN) or a designated team member. The 
consultant/RN will introduce the study to the patient 
and provide her with the patient information sheet as 
appropriate, answer any queries, and if appropriate the 
participant may sign the consent form, receive the base-
line assessment pack for completion at home and bring 
back on the day of surgery or send back to the site using 
prepaid post.
Patients whose first approach is at the clinic will be 
given as much time as they require to consider participa-
tion; patients may make a decision to participate at this 
time or may agree to be contacted at home by the local 
RN. If a patient agrees to be contacted at home, she will 
receive a telephone call from the local RN to discuss any 
queries. If a patient agrees to the study at that stage, then 
arrangements will be made for baseline assessment and 
consenting; this could be done as a separate appointment 
or at a preadmission clinic. As above, participants can 
complete the baseline assessment pack at home and bring 
back on the day of surgery or send back to the site using 
prepaid post. These arrangements can be individualised 
for each centre.
Informed consent
The patient information leaflet explains that the trial is 
investigating the use of either adjustable SIMS or tension-
free SMUS for the surgical management of SUI in women. 
All participants will sign informed consent forms. Partic-
ipants who cannot give informed consent (eg, due to 
incapacity) will not be eligible for participation. Pending 
their permission, the participants’ permission, the general 
practitioner (GP) will be informed of their participation.
group.bmj.com on August 25, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
 7Abdel-Fattah M, et al. BMJ Open 2017;7:e015111. doi:10.1136/bmjopen-2016-015111
Open Access
Randomisation and allocation
Eligible and consenting participants will be randomised 
to one of the two study groups in a 1:1 allocation ratio 
using the randomisation application at the trial office at 
the Centre for Healthcare Randomised Trials (CHaRT). 
This randomisation application will be available 24 hours 
a day, 7 days a week as both an interactive voice response 
telephone system and as an internet-based application. 
The randomisation will use a minimisation algorithm 
based on centre and previously supervised PFMT within 
the last 2 years (PFMT: yes/no). Women will be further 
randomised to receive short versus detailed sexual func-
tion questionnaire.
Follow-up procedures
Eligible patients who have given signed informed consent 
to participate in the study will be randomised to either 
SIMS or SMUS. They will be asked, at baseline, to complete 
the preoperative questionnaire pack, which includes 
few questions on participants’ demographic details and 
preoperative health/medications. It also includes vali-
dated questionnaires for symptom severity of UI and its 
impact on QoL and sexual function: the EQ-5D, ICIQ-
SF, Urgency Perception Scale (UPS), ICIQ-LUTSqol, 
ICIQ-FLUTS and ICIQ-FLUTS-Sex (or PISQ-IR), and to 
perform 24-hour pad test and home continence stress 
test (see online supplementary appendix 3, objective 
assessment of urinary incontinence within the SIMS trial 
— protocol).
On days 1–14 they will be asked to complete the pain 
score and use of analgesics questions by self-completed 
postoperative diary. At 4 weeks postoperatively, partic-
ipants will be asked to complete a short questionnaire 
(on the last section of the diary) to capture pain, use of 
analgesia, complications, return to work/normal activ-
ities, PGI-I and EQ-5D. At 3 months postoperatively, 
participants will be asked to complete a number of ques-
tionnaires — to measure the PGI-I, EQ-5D, ICIQ-SF, UPS 
and questions related to health services resource — and 
to report any complications or further treatment received 
for UI. In addition, at 12, 24 and 36 months postran-
domisation, participants will be asked to complete a 
questionnaire to measure the PGI-I, recurrence, further 
treatment received and questions related to health 
services resource use, in addition to all baseline assess-
ment pack. Taking into account the inevitable waiting 
time between randomisation and receiving the surgical 
treatment (average surgical waiting list is 8–12 weeks), 
and in addition the clinical importance of assessing the 
outcomes at 12 months postoperatively, we aim to send 
the 1-year follow-up pack at 15 months postrandomis-
ation. This strategy will ensure that the vast majority of 
participants are at least 12 months postoperative at time 
of capturing the primary outcome. In addition, at 20 
months participants will be asked to fill out an additional 
economic data questionnaire, which will include the 
patient time and travel costs questionnaire. Sending this 
questionnaire at 20 months will minimise patient burden 
when completing the annual questionnaire. The discrete 
choice experiment (DCE) will be completed at the end of 
the 3-year follow-up period.
Questionnaires and up to two reminders will be sent 
to participants by post. Non-responders to the 12-month 
postrandomisation questionnaire will be contacted 
by phone for a short interview to capture the primary 
outcome (PGI-I; a single item question to mark the 
outcome of the operation as described in section 5.1). 
If the participant indicates at this phone call her wish 
to withdraw from the study, a ‘Change of Status Form’ 
will be completed as below. Participants will be sent a 
voucher (of modest value) as a token of appreciation 
for completion and return of the 3-month and follow-up 
questionnaires.
Change of status/withdrawal procedures
Participants will remain on the trial unless they choose to 
withdraw consent or if they are unable to continue for a 
clinical reason. If a participant withdraws consent, partic-
ipant questionnaires will not be collected. A member of 
the research team will contact the participant by phone 
and complete the ‘change of status form’, which includes 
the participant’s instructions on what parts, or whole, 
of the study they may wish to withdraw from. Unless a 
participant specifically declines, the research team will 
continue to collect relevant data from their healthcare 
records such as ONS and NHS central registries. Except 
for formal withdrawal of consent, all other changes in 
status will mean the participant is still followed up for all 
study outcomes wherever possible.
subsequent arrangements (if applicable)
Informing key people
Following formal trial entry, the Study Office will inform 
the participant’s GP via a letter detailing information 
about the SIMS study and the Study Office contact details.
The local RN will file the hospital copy of the consent 
form in the hospital notes along with information about 
SIMS, give one copy to the patient, file one copy to the 
local site file and send one copy to the Study Office in 
Aberdeen.
1. use the SIMS internet database to enter data regarding 
the participant, including data required to complete 
randomisation
2. data entry onto the study database as soon as practical
3. forward a copy of study documentation when and as 
requested by the Study Office in Aberdeen to facilitate 
quality control.
Notification of/by GPs
GPs are asked to contact the Study Office if one of the 
participants moves, becomes too ill to continue or dies, 
or any other notifiable event or possible serious adverse 
event occurs. Alternatively, staff at the Study Office may 
contact the GP.
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sAfEty
The SIMS trial involves procedures for the surgical 
management of SUI in women which are well established 
in clinical practice. However adverse effects may occur 
during or after any type of surgery.
definitions
An adverse event (AE) is any untoward medical event 
affecting a clinical trial participant. Each initial AE will 
be considered for severity, causality or expectedness, and 
may be reclassified as a serious event.
AEs are not:
 ► continuous and persistent disease or symptom, pres-
ent before the trial, which fails to improve, such as ur-
gency, urgency incontinence, VD, pain or dyspareunia
 ► treatment failure: persistence or recurrence of UI
 ► worsening pain or where the site of pain changes is 
an AE.
A serious adverse event (SAE) is any AE that:
 ► results in death
 ► is life-threatening (ie, the participant was at risk of 
death at the time of the event; it does not refer to an 
event that hypothetically might have caused death if it 
was more severe)
 ► results in persistent or significant disability or incapac-
ity
 ► requires an unplanned readmission to the hospital 
(defined as ‘participant admitted as an in-patient with 
≥1 night hospital stay’); this excludes hospital ward at-
tenders for minor issues such as lower urinary tract 
infection, voiding difficulties or other issues consid-
ered by the PI to be minor; this information will be 
routinely collected on the postoperative form and/or 
the supplementary hospital visit form as appropriate
 ► requires prolongation of existing hospitalisation (de-
fined as >36 hours postoperative hospital stay); this ex-
cludes prolongation of hospital stay for minor issues 
such as voiding difficulties; such information will be 
routinely collected on the operation and clinical data 
form; prolongation of hospital stay due to social/geo-
graphical reasons will not be considered
 ► is otherwise considered medically significant by the 
investigator.
Note: Hospitalisations for treatment planned prior 
to randomisation and hospitalisation for elective treat-
ment of a pre-existing condition, or complication 
arising from either, will not be considered as an (S)AE.
specific expected AEs
In this surgical trial the following events are potentially 
expected:
 ► Intraoperative complications: bleeding, bladder/ure-
thral injury, bowel injury, nerve injury (obturator/
dorsal nerve of clitoris), injury to blood vessels, hyper-
sensitivity to the local/general anaesthetics and/or 
any of the medications or materials used, pain, shak-
ing/dizziness, change of procedure or device and/or 
type of anaesthesia
 ► Immediate postoperative complications: pain in the 
hip/ thigh or the vagina, infection (chest, urinary 
tract), bleeding, fever, haematuria, syncope, dizziness, 
voiding difficulties/urinary retention and thrombo-
embolism
 ► Later postoperative complications: pain in the hip/
thigh or the vagina, mesh extrusion, mesh erosion to 
the vagina or LUT, haematoma, abscess formation and 
nerve injury; in addition, new onset or worsening of 
any of the following: dyspareunia, vaginal discharge, 
voiding difficulties/urinary retention, long-term 
self-catheterisation, urgency/urgency incontinence.
Procedures for detecting, recording, evaluating and 
reporting AEs and SAEs
Detecting AEs and SAEs
All AEs and SAEs must be recorded from the time a 
participant consents to join the study until follow-up is 
complete.
Follow-up questionnaires will enquire about any AE/
SAE occurrence; in addition, participants will also be 
asked if they have been admitted to hospital and/or seen 
a healthcare professional.
Recording AEs and SAEs
Depending on severity, when an AE/SAE occurs, it is the 
responsibility of the investigator (or delegated medical 
personnel) to review appropriate documentation (eg, 
hospital notes, laboratory and diagnostic reports) related 
to the event. The investigator (or the delegated medical 
personnel) should then record all relevant information 
in the CRF and if required on the SAE form.
Information on SAE to be collected includes type and 
date of event, investigator assessment of severity and 
causality and any investigation/treatment required.
Planned hospital visits for conditions other than 
those associated with UI and/or its treatment will not 
be collected or reported. Further UI treatment will be 
recorded as a secondary outcome measure, but will not 
be reported as SAEs.
Evaluating AEs and SAEs
All AEs will be assessed in respect of seriousness, rela-
tionship to study intervention, whether expected or 
unexpected, and therefore whether constituting an SAE 
by the local PI, chief investigator or their deputies.
Assessment of seriousness
The investigator should make an assessment of serious-
ness as defined in section 4.1.
Assessment of causality
The investigator must make an assessment of whether 
the AE/SAE is likely to be related to any of the research 
procedures according to the following definitions:
 ► Related: resulted from any of the procedures required 
by the protocol, whether or not this procedure is the 
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specific intervention under investigation, and wheth-
er or not it would have been administered outside the 
study as normal care
 ► Unrelated: where an event is not considered to be re-
lated to any of the research procedures.
Assessment of severity
The investigator should make an assessment of severity 
for each AE/SAE and complete an SAE form should any 
of the SAE criteria in section 4.1 be met.
Assessment of expectedness
When assessing expectedness refer to the expected events 
(section 4.1).
The following is an example of the assessment of an AE: 
intraoperative bleeding will be collected as an AE on the 
operative form; however if >500 mL, an SAE form will be 
completed.
Reporting AEs and SAEs
Reporting responsibilities of the chief investigator
When an SAE form is uploaded onto the trial website, the 
trial manager and chief investigator will be automatically 
notified. The chief investigator or trial manager will notify 
the sponsor within 24 hours of receiving completed forms 
for ‘un-expected’ and 7 days of receiving completed forms 
for an ‘expected’ SAE. The sponsor will then provide the 
final assessment of the SAE.
The chief investigator (or trial manager) will report 
any ‘related and unexpected SAEs’ to the main Research 
Ethics Committee (REC) and the data monitoring 
committee (DMC) within 15 days of the chief investigator 
becoming aware of it. All other SAEs will be summarised 
and reported to the ethics committee, the funder, the 
DMC and the Trial Steering Committee (TSC) in their 
regular progress reports.
If all the required information is not available at the 
time of reporting, the investigator must ensure that any 
missing information is provided as soon as this becomes 
available. It should be indicated on the report that this 
information is follow-up information of a previously 
reported event.
outCoME MEAsurEs
This RCT assesses and compares the adjustable anchored 
SIMS versus tension-free SMUS with up to 3-year 
follow-up, in terms of patient-reported success rates, 
objective success rates, impact on urinary symptoms, 
complications, recovery, health-related QoL and sexual 
function, and costs to health services
Primary outcome measure
The primary outcome measure will be patient-reported 
success rate measured by the validated PGI-I at 12 months. 
Patient-reported success rates reflect patients’ experience 
compared with the objective measures, which can overes-
timate the success of SUI surgery.27 The primary outcome 
is assessed by the PGI-I, a one-item questionnaire 
designed to assess the patient’s impression of changes 
in her urinary symptoms. The PGI-I asks the patient to 
best describe her urinary symptoms, compared with how 
they were before the study intervention, on a 7-point 
scale scored as (1) ‘very much better’, (2) ‘much better’, 
(3) ‘a little better’, (4) ‘no change’, (5) ‘a little worse’, 
(6) ‘much worse’ or (7) ‘very much worse’. ‘Success’ will 
be defined as responses of ‘very much better’ or ‘much 
better’; this will determine whether the women are 
satisfied with their operation and hence consider their 
symptoms are resolved and not seek further treatments. 
The primary economic outcome will be incremental cost 
per QALY gained at 12 months. The above measures will 
also be assessed at 2 and 3 years.
secondary outcome measures
The following are the secondary outcome measures:
 ► complications including LUT injuries, haemorrhage 
(blood loss ≥200 mL), postoperative VD, pain, mesh 
extrusion/erosion, dyspareunia, long-term self-cath-
eterisation, new-onset or worsening urgency/urgen-
cy incontinence, assessed as appropriate at 3 and 12 
months, then yearly up to 3 years
 ► postoperative pain using a pain Numerical Rating 
Scale, assessed days 1–14
 ► objective success rates: assessed by 24-hour pad test at 
12 months and yearly up to 3 years
 ► other LUT symptoms using the ICIQ-FLUTS long 
form and/or short form (ICIQ-SF) at 3 and 12 months 
and yearly up to 3 years
 ► health-related QoL profile (area under the curve) 
derived from EQ-5D, pain scores and ICIQ-LUTSqol 
measurements at 1, 3 and 12 months and yearly up to 
3 years
 ► impact on sexual function derived from ICIQ-FLUT-
Sex/or PISQ-IR measurements at 12 months and year-
ly up to 3 years
 ► recurrence of SUI, reoperation rates for SUI, further 
treatment received such as physiotherapy, medical 
treatment (selective noradrenaline reuptake inhibi-
tors and/or antimuscarinic treatment).
The secondary economic outcomes include the 
following:
 ► NHS and patient primary and secondary care resource 
use and costs at 12 months and yearly up to 3 years
 ► incremental cost-effectiveness derived from respons-
es to the ICIQ-LUTS over the follow-up period at 
12 months and yearly up to 3 years
 ► incremental net benefit (NB) calculated from the re-
sponses to the DCE at the end of the 3-year follow-up.
We will use the same assessment tools and QoL instru-
ments used in our pilot RCT, which observed a 97% 
response rate.
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dAtA CollECtIon And ProCEssIng
Measuring outcomes
Participant follow-up questionnaires will be triggered by 
date of surgery up to 3 months, then by date of randomi-
sation thereafter.
schedule of data collection
The components of follow-up are shown in table 1.
data processing
Participants will be sent the follow-up questionnaires 
directly from the Study Office in Aberdeen and asked 
to return the completed questionnaires in prepaid enve-
lopes. RNs will enter locally collected data in the centres. 
The Study Office will work closely with local (RNs) to 
ensure the data are complete and accurate. Extensive 
range and consistency checks will further enhance the 
quality of the data.
sAMPlE sIzE, ProPosEd rECruItMEnt rAtE And 
MIlEstonEs
Sample size
A non-inferiority design is appropriate for this trial 
because the proportion having success at 12 months in 
women managed with SMUS is high. Adjustable anchored 
SIMS is not hypothesised to increase this proportion, 
however may have other potential benefits as outlined 
previously. It is therefore important to show that SIMS 
is clinically non-inferior to SMUS and to measure these 
other dimensions (such as cost-effectiveness, mediated 
through shorter stay and earlier recovery, QoL mediated 
through less pain, and any safety signals via the complica-
tion rate) in an adequately powered, pragmatic RCT with 
long enough follow-up. It is essential therefore that the 
study is powered to demonstrate non-inferiority within 
an appropriate margin, and hence this clinical outcome 
is the correct choice as primary outcome. A 10% inferi-
ority margin has been deemed by expert clinicians as the 
maximum inferiority margin in clinical effectiveness that 
would be accepted should SIMS prove to be superior in 
other outcomes such as shorter hospital stay, less postop-
erative pain, earlier recovery and more cost-effective. In 
such case, adjustable anchored SIMS would then reliably 
be able to be considered as a first-line surgical treatment 
of women with primary SUI.
Published literature suggests that P1, the percentage 
success rate at 12 months in the SMUS arm, will be about 
85%; identical results were confirmed by our pilot RCT. 
Estimating P2, the percentage of success in the adjust-
able anchored SIMS arm, is more difficult due to lack 
of published evidence; a crude meta-analysis of the 
12-month outcome data from our multicentre pilot RCT 
and few other small studies indicates a similar P2 of 85%.
Power estimates were explored by simulating trials of 
fixed sample size (using equal allocation) with binary 
responses generated by P1=85% and P2=85%. Power 
was then estimated as the proportion of simulated trials 
where the lower bound of the two-sided CI satisfied P1-P2 
> −10%. Simulations, run in Stata V.11.2 show that a trial 
of 275 per arm or 550 in total is required for the lower 
bound of the estimated 95% CI to rule inferiority at the 
specified level with 90% power. Adjustment for potential 
15% dropout inflates the trial to 650 in total. For compar-
ison, a trial of this size would have above 80% power to 
test superiority on secondary outcomes of difference in 
means of size one-quarter of an SD (or 90% power to 
detect an effect size of 0.28 SD).
In our multicentre pilot RCT,17 131/137 women 
(95.6%) completed the 12-month follow-up and showed 
no significant differences in the patient-reported success 
rate (OR 0.895; 95% CI 0.344 to 2.330; p=1.000) between 
adjustable anchored SIMS (Ajust) and SMUS (TVT-O) 
groups. These results, together with similar results from 
other studies detailed above,16–21 provide assurances for 
the reliability of our sample size calculations. A statistical 
reviewer previously queried whether we had considered 
the implications if in fact the success of the two proce-
dures were not identical but slightly different. If we 
consider success rates of 84% and 85%, the study retains 
90% power to detect a slightly larger margin of non-infe-
riority of around 11%, and so to all intents and purposes 
a sample size of 650 remains adequate.
recruitment rates and milestones
Our recruitment rate estimates are based on data from 
the pilot multicentre RCT comparing adjustable anchored 
SIMS (Ajust) with SMUS (TVT-O). We believe that these 
centres are representative of the UK; 137 women were 
recruited across six centres at a rate of 3.4 per centre per 
month. Overall, 137/181 (76%) patients were willing to be 
randomised; however, we have used a more conservative 
estimate of 50% in our recruitment projection. There-
fore, it has been estimated that in order to approach 1300 
eligible patients to randomise the required 650 patients, 
25 centres would need a throughput of at least 90 eligible 
patients per centre per year to recruit three patients per 
month. The recruitment projection is based on 18 months 
of recruitment (months 7–24 inclusive) and allows for 
set-up, holidays and waiting list times. We expect a stag-
gered recruitment of centres with all centres active by the 
end of month 18. The first 45 patients will be recruited by 
month 12, 256 patients by month 18 and the remaining 367 
patients by month 24, making a total of 668 patients.
Due to lower than predicted recruitment, a further exten-
sion has been granted to enable recruitment to reach at 
least 600 participants This increases the recruitment period 
so that the last participant will be recruited in month 44. 
Please see the Gantt chart (figure 2) and recruitment 
projection (online supplementary appendix 4).
AnAlysEs PlAn
Statistical analysis
Treatment groups will be described at baseline and 
follow-up using numbers (with percentages), means (with 
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SD) and medians (with IQRs) where relevant. Primary and 
secondary outcomes will be compared using generalised 
linear models, with adjustment for design covariates. As 
standard we also adjust all our surgical RCTs for centre/
surgeon effects; adjustment for centre/surgeon will be by 
random effect in the trial analysis.
For the primary outcome, we plan to dichotomise the 
PGI-I responses with ‘success’ defined as ‘very much better’ 
or ‘much better’ and the rest of responses as failures; this will 
determine whether the women are satisfied with their oper-
ation and hence consider their symptoms are resolved and 
do not seek further treatments. In addition, this definition 
of ‘success’ is widely used within the research field of surgical 
treatment of SUI and was used in our pilot RCT, and there-
fore will allow comparing our results with other trials in the 
literature. We will also perform a secondary analysis using 
ordinal regression on the 7-point PGI-I scale, so potentially 
using more of the information in the outcome. However, 
we do not propose adopting this ordinal regression as the 
primary analysis since the underlying proportional odds 
model makes strong assumptions about the consistency of 
treatment effect across the levels of response, and partic-
ularly in the context of a non-inferiority design there may 
be departures from those assumptions that would interfere 
with establishing whether the simple hypothesis around the 
non-inferiority of the binary ‘success’ under the two opera-
tions had been shown.
The statistical analysis of the primary outcome will 
be by the usual intention-to-treat (ITT) and also a suit-
ably defined per-protocol analysis (to reflect the unique 
nature of non-inferiority designs and the issue that ITT 
for such designs may not be the most conservative anal-
ysis and inflate the true type I error rate, given that in 
a non-inferiority design the null hypothesis is that the 
interventions are not non-inferior or equivalent). If the 
two approaches return material differences in interpre-
tation, this will be investigated carefully. Results will be 
displayed as estimates and 95% CIs derived from appro-
priate generalised linear models. CIs around observed 
differences will then be compared with the prespecified 
non-inferiority margin.
Secondary outcomes will be analysed similarly. 
Outcomes such as postoperative pain will be assessed 
under a superiority hypothesis as we believe that this 
will be lower in the intervention arm. As stated in the 
sample size section, there is above 80% power to detect 
a difference of a quarter of an SD under a superiority 
hypothesis.
All analyses will follow a carefully documented statis-
tical analysis plan. Subgroup analyses (appropriately 
analysed by testing treatment by subgroup interaction) 
will explore possible treatment effect modification. The 
following are the prespecified subgroups:
 ► mixed incontinence versus pure stress incontinence
 ► urodynamic versus clinical diagnosis of SUI
 ► adjustable anchored SIMS versus each type of SMUS 
(ie, RP-TVT and TO-TVT separately)
 ► comparison of the main types of SIMS
 ► we will also include an exploratory subgroup analysis 
comparing those above and below the observed medi-
an age of the recruited women using a formal test of 
interaction
 ► responses to two validated sexual function question-
naire: ICIQ-FLUT-Sex versus PISQ-IR.
Effect of pregnancy
MUS procedures are generally offered to women after 
having completed their families, and therefore subse-
quent pregnancy is usually a rare event that is unlikely 
to be balanced between both trial arms. If a woman falls 
pregnant after receiving treatment within the RCT, her 
data will be censored at the time of confirmed pregnancy 
for the primary analysis. This small number of women will 
still be followed up for all outcome data as usual, and if 
the numbers warrant, a sensitivity analysis including them 
will be undertaken on the primary outcome.
The TSC and an independent Data Monitoring and 
Ethics Committee will be asked to review and comment 
on the statistical analysis plan prior to analysis. There are 
no plans for any formal interim analyses to be seen by the 
DMC. A single main analysis will be performed on the 
12-month primary outcome and repeated on the 2-year 
and 3-year outcomes. The DMC will meet before recruit-
ment begins, or as soon as practical, to agree the Terms of 
Reference and other procedures.
EConoMIC EvAluAtIon
Our primary health economic evaluation will be from a 
health service provider’s (NHS) perspective; however, we 
will also present data from a wider societal perspective. 
Figure 2 SIMS study Gantt chart. SIMS, Single-incision mini-slings.
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These data will include costs to patients of time and 
travel, costs to carers and family members, and costs to 
society as a whole, estimated from lost productivity as a 
result of time off work/away from normal activities.
Collection of resource use and cost data
Healthcare resource use will be collected using 
patient-administered questionnaires asking patients to 
retrospectively recall their contacts with healthcare profes-
sionals relating to their incontinence. This questionnaire 
will be administered at 3 and 12 months, then yearly 
for 3 years. It is generally accepted that patient recall is 
accurate up to 12 months, and it is highly unlikely that a 
patient would not remember significant events relating 
to their disease over this time period. Data collected 
will include secondary care contacts (hospital inpatient 
admissions, outpatient appointments) and primary care 
contacts (eg, GP contacts, nurse contacts, physiotherapist 
consultations) and prescription drug medications. These 
healthcare utilisation data will be combined with unit cost 
information for the use of specific resources using stan-
dard sources.29–31 Data on costs for each group (SIMS and 
SMUS) will be summed to provide an average cost per 
patient trial participant. Sensitivity analysis will be used to 
explore various distributions of cost data as well as various 
methods for the imputation of missing and censored 
data. We will provide a comprehensive range of determin-
istic sensitivity analyses to test any assumptions we make 
in our analysis on the overall results. For example, we will 
test best and worst case scenarios for the intervention cost 
(whether all procedures in the SIMS arm are conducted 
under GA or LA). The impact of any missing data and 
methods of data imputation on our results will also be 
tested. We will test the impact of these and a range of 
other sensitivity analyses to be determined as the trial 
progresses on all our results (eg, cost utility analysis and 
cost benefit analysis).
Participant costs
Out-of-pocket patient expenses (including the purchase 
of containment products), private healthcare costs, travel 
costs and costs associated with lost days at work will also 
be collected using the patient-administered question-
naire and incorporated into the patient perspective 
analysis. Costs of family members and/or carers will also 
be collected as part of the trial and reported.
QuAlIty of lIfE
Health state valuations will be based on the responses 
to the ICIQ-LUTSqol (baseline, 3, 12 months and annu-
ally over the follow-up period) and EQ-5D administered 
at baseline, 1, 3 and 12 months and annually over the 
follow-up period. These data will be transformed into 
utility values using standard algorithms. QALYs will be 
calculated, using the area under the curve methods, with 
any differences between groups being reported. Both 
measures will be compared and contrasted and tested for 
comparability in measuring outcomes for these women.
Cost-EffECtIvEnEss
The analysis will use the estimates of mean costs and 
QALYs as described for each trial participant to estimate 
the incremental cost-effectiveness ratio at 12-month 
follow-up period and where appropriate the analysis 
will mirror that of the statistical analyses. Cost-effective-
ness (cost per QALY gained) will also be reported over 
the 3-year follow-up period. The results of the analysis 
will be presented as incremental costs, effects and incre-
mental cost per QALY. Bootstrapping of cost and QALY 
differences, as well as a range of one-way and multiway 
deterministic sensitivity analyses, will be conducted to 
address uncertainty in the estimates. Cost per QALY data 
will also be presented in the form of cost-effectiveness 
acceptability curves.
dIsCrEtE ChoICE ExPErIMEnt
Previous research32 has suggested that EQ-5D question-
naire may not fully capture the benefits from successfully 
treating incontinence. They may not fully represent 
patient preferences for treatments and their associated 
outcomes. Therefore, we will conduct a DCE to elicit 
preference for the process, patient experience and health 
outcomes. A DCE presents respondents with a series of 
hypothetical choices that describe the choice alternatives 
by their underlying attributes; respondents are asked 
to choose the alternative they prefer. The values of the 
attributes vary across choice scenarios; by observing the 
peoples’ choices, it is possible to infer their preferences 
over the attributes of each surgical procedure. The extent 
to which an individual values an intervention depends on 
the levels of these attributes.33 DCEs are commonly used 
to identify people’s preferences in a variety of non-market 
situations/services/commodities.34–36
The attributes and levels for the DCE will be informed 
by systematic literature searching and advice sought from 
clinical experts. Attributes might include preferences for 
general/local anaesthetic, preferences for pain levels, 
cure and improvement rates, impact on activities of 
daily living, and so on. These attributes and levels will be 
combined to identify profiles that will be used to develop 
scenarios to present the study participants. The ques-
tionnaire will be piloted among a convenience sample to 
refine all practical aspects of the survey and to ensure that 
trade-offs can be made between the identified attributes. 
Once the pilot is complete and the questionnaire has 
been refined, it will be administered to the trial partici-
pants at the end of the 3-year follow-up.
Experimental design techniques will be used to 
generate an efficient set of choices from which prefer-
ences will be estimated. Logistic regression techniques 
will be used to analyse the response data. A cost attri-
bute will be included so that willingness to pay (WTP) 
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can be estimated. The results of the DCE information will 
be combined with the clinical outcomes estimated from 
the trial to provide an estimate of mean WTP for each 
of the two interventions. Results of the WTP aspect of 
the DCE will be presented as incremental NB between 
groups, where NB will be measured as WTP less the 
mean cost for each intervention. The intervention with 
the greatest NB will be deemed the most efficient. The 
results of this analysis will be compared and contrasted 
with the cost/QALY outcomes and will yield some infor-
mation regarding the applicability of traditional QALY 
measurement to conducting economic evaluation in UI. 
The resultant costs and utilities will be used to estimate 
preference-based quality weights for this condition.
orgAnIsAtIon: trIAl MAnAgEMEnt And ovErsIght 
ArrAngEMEnts
Study Office in Aberdeen
The SIMS trial is managed by the Study Office at the 
CHaRT based within the Health Services Research Unit 
(HSRU), University of Aberdeen. The staff in the Study 
Office, led by the trial manager, provides the day-to-day 
support for the clinical centres. The data coordinator 
organises all clerical aspects, including the postal ques-
tionnaires (mailing, tracking and entering returned 
data using the study web data entry portal). A quality 
assurance manager oversees and ensures the implemen-
tation CHaRT’s standard operating procedures for trials, 
including observance of the appropriate principles of 
Good Clinical Practice.
At the centres, the RNs (or recruitment coordinators) 
are responsible for all local processes involved in iden-
tifying, consenting, randomising the participants, and 
ensuring the completion of the study baseline assessment 
and completion of the surgical intervention research 
records.
The SIMS Study Office team will meet formally at least 
monthly during the course of the study to ensure smooth 
running and troubleshooting.
local organisation in sites
The local PI and RN will be responsible for all aspects 
of local organisation, including identifying, consenting 
and randomising the participants, along with facilitating 
the delivery of the intervention and notification of any 
problem or unexpected developments for the duration of 
the trial. They will be responsible for ensuring that study 
data are collected for baseline assessments, collecting and 
recording participant study data on study-specific case 
report forms and logging all the details onto the remote 
web-based data capture system as soon as practical after 
completion. The local PI will return all study documents 
to the Study Office in Aberdeen when requested.
Project Management group
The study will be supervised by a Project Management 
Group (PMG). The chair of this group will be the chief 
investigator (Mohamed Abdel-Fattah) and will consist 
of representatives from the Study Office and grant 
holders. The PMG will meet every 3 months, including 
face to face in month 1 and month 6 in the first year. 
It is expected that, once the project is underway, the 
majority of these meetings will be held by teleconfer-
ence; however, the PMG will also meet face to face at 
least annually. In addition, the PMG will also meet at 
the annual TSC meeting.
trial steering Committee
The study is overseen by a TSC. The membership of this 
committee comprised four independent members along 
with the chief investigator or a nominated delegate. The 
trial sponsors, other SIMS grant holders and key members 
of the central office (eg, the trial manager) can partici-
pate in TSC meetings but are not members. The funders 
will be notified in advance of meetings and a represen-
tative will be invited to attend. Other relevant experts 
may be invited to attend as appropriate. Details of the 
membership of the TSC can be found at the start of this 
protocol. CHaRT has adopted the TSC Charter adapted 
from the DAMOCLES Charter for DMCs and suggests 
to the independent TSC members that they adopt the 
Terms of Reference contained within. The TSC will meet 
approximately yearly.
data monitoring committee
An independent DMC is made up of members listed 
at the start of this protocol, one of whom is an experi-
enced statistician. The DMC will initially meet to agree 
its Terms of Reference. CHaRT has adopted the DAMO-
CLES Charter for DMCs and suggests to the independent 
DMC members that they adopt the Terms of Reference 
contained within.
The DMC meets regularly to monitor the study data, 
including unblinded trial data and any reported SAEs. If 
required, the DMC would make recommendations as to 
any modifications required to be made to the protocol or 
the termination of all or part of the trial.
rEsEArCh govErnAnCE, dAtA ProtECtIon And 
sPonsorshIP
Research governance
The trial will be run under the auspices of CHaRT based 
at HSRU, University of Aberdeen. This will ensure 
compliance with research governance and provide 
centralised trial administration, database support and 
economic and statistical analyses. CHaRT is a registered 
clinical trials unit with particular expertise in running 
multicentre RCTs of complex and surgical interven-
tions.
The PMG will ensure through the TSC that adequate 
systems are in place for monitoring the quality of the 
study and appropriate expedited and routine reports, to 
a level appropriate to the risk assessment of the study.
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data protection
All trial data will be kept strictly confidential and accessed 
only by the relevant members of the trial team. Partici-
pants’ details will be stored on a secure database under the 
guidelines of the 1998 Data Protection Act, and regular 
checks and monitoring are in place to ensure compli-
ance. Data are stored securely in accordance with the Act 
and archived to a secure data storage facility. The senior 
IT manager (in collaboration with the chief investigator) 
will manage access rights to the data set. Participants 
will be allocated an individual specific trial number and 
their details will be anonymised on the secure database. 
We anticipate that anonymised trial data may be shared 
with other researchers to enable international prospec-
tive meta-analyses. To comply with the 5th Principle of the 
Data Protection Act 1998, personal data will not be kept 
for longer than is required for the purpose for which it 
has been acquired.
sponsorship
The University of Aberdeen and NHS Grampian are the 
cosponsors for the trial.
QuAlIty AssurAnCE
The trial will be monitored to ensure that the study is 
being conducted as per protocol, adhering to research 
governance and the appropriate regulations. The 
approach to, and extent of, monitoring (specifying both 
central and on-site monitoring) will be specified in a trial 
monitoring plan, which is usually initially determined by 
a risk assessment, undertaken prior to start of trial.
dAtA hAndlIng, rECord kEEPIng And ArChIvIng
Clinical data will be entered into the database by the 
local investigator and/or RN working in each hospital 
site, together with data from questionnaires completed 
at clinic. Questionnaires returned by post to the trial 
office will be entered there. Staff in the trial office will 
work closely with local RNs to ensure that the data are as 
complete and accurate as possible. Extensive range and 
consistency checks will further enhance the quality of the 
data.
The cosponsors are responsible for ensuring that trial 
data are archived appropriately. Essential data shall be 
retained for a period of at least 10 years following close 
of study.
sAtEllItE studIEs
It is recognised that the value of the study may be 
enhanced by smaller ancillary studies of specific aspects. 
Plans for these will be discussed in advance with the PMG. 
REC approval will be sought for any new proposal, if 
appropriate.
EthICs And rEgulAtory APProvAls
Ethics approval
The North of Scotland REC has reviewed and approved 
this study. The study will be conducted according to 
the principles of good clinical practice provided by the 
research governance guidelines. We believe this study 
does not pose any specific risks to individual participants 
beyond standard surgical procedures, nor does it raise 
any extraordinary ethical issues. Annual progress reports 
and a final report at the conclusion of the trial will be 
submitted to the North of Scotland REC within the time-
lines defined in the regulations.
finance and insurance
The trial is funded by a grant awarded by the NIHR Health 
Technology Assessment programme. The necessary trial 
insurance is provided by the University of Aberdeen.
Authorship and publication policy
All RCTs conducted by CHaRT have a commitment 
to publish the findings of the research. At a minimum 
this trial will have a results paper published in a peer-re-
viewed medical/scientific journal. If all grant-holders 
and researcher staff fulfil authorship rules, group author-
ship will be used under the collective title of ‘the SIMS 
Trial Group’. The chief investigator and possibly other 
members of the trial group will take responsibility for 
drafting the paper, and this will be recognised by line ‘the 
CI (as primary author), followed by the other authors and 
the SIMS Trial Group’.
For reports that arise from the trial but where some 
members do not fulfil authorship rules (eg, specialist 
substudy publications), authorship should be attributed 
to chief investigator and the named individual(s) for the 
SIMS Trial Group.
To safeguard the integrity of the main trial, reports of 
explanatory or satellite studies will not be submitted for 
publication without prior arrangement from the PMG.
We intend to maintain interest in the study by publi-
cation of SIMS newsletters at intervals for staff and 
collaborators. Once the main report has been published, 
a lay summary of the findings will be sent in a final SIMS 
newsletter to all involved in the trial. Further details on 
the publication policy can be found in online supplemen-
tary appendix 5.
dIsCussIon
The SIMS study is a key outcome study that should answer 
the important research question of whether adjustable 
SIMS should be used in clinical practice as a first-line 
surgical treatment option for women with primary SUI.
This study is a pragmatic, patient-oriented trial aiming 
to capture a true representation of the actual patient 
population. The inclusion/exclusion criteria were chosen 
to allow the capturing of the relevant patient group.
This trial seeks to follow standard pathways of care with 
the only additional intervention being randomisation 
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between the two treatment strategies under test and 
collection of baseline and outcome information.
The results will inform clinicians and policy makers on 
the cost-effectiveness of this relatively new technology 
compared with the SMUS. The long-term follow-up 
in the SIMS study is crucial to address the long-term 
successes rate and AEs of MUS in general and SIMS in 
specific.
dissemination
The dissemination plans include (1) Health Technology 
Assessment Program monograph, (2) presentation 
at international scientific meetings, (3) publications 
in high-impact, open-access, peer-reviewed journals, 
and (4) presentations at health economic and health 
services research meetings. The results of the trial will 
be included in the updates of NICE and the European 
Association of Urology guidelines; these two specific 
guidelines directly influence practice of all the UK and 
worldwide specialists, respectively. In addition, a plain 
English-language summary of the main findings and 
results will be presented for relevant patient organi-
sations and communities, including the bladder and 
bowel foundation. This will ensure user relevance in 
dissemination of the results.
trial status
The SIMS study is currently recruiting in 20 UK research 
centres. The first patient was randomised on 4 February 
2014, with follow-up to be completed at the end of 
February 2020.
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